Physician profile
Alwin W Bagingito
NPI 1821172065
$9,886.57
in general payments reported to CMS, 2019-2025
38 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $2,216 · 2021: $2,697 · 2022: $1,061 · 2023: $806 · 2024: $740 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,184 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,974.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,201.16 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,149.31 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $921.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $827.45 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Amgen INC. | $436.06 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $375.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $340.11 | 2020-2024 | Arexvy |
| Allergan, INC. | $313.09 | 2019-2021 | |
| Pfizer INC. | $284.93 | 2019-2024 | |
| Lilly USA, LLC | $277.60 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $232.13 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $223.57 | 2019-2022 | |
| Medtronic, INC. | $174.65 | 2022-2023 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $108.02 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alwin Bagingito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.